Project Grant R21CA302991
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $394K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $406,611 to the University of Texas Health Science Center at Houston (UTHealth) to identify the role and signaling mechanisms of the GPR56 protein in colorectal cancer progression and therapy resistance. The project aims to develop and evaluate novel antibody-drug conjugates and combination therapies targeting GPR56 for the improved treatment of colorectal cancer. Key activities...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) for $482,236 supports research to investigate methods for reverting resistance to the antibody-drug conjugate trastuzumab deruxtecan (T-DXD) in HER2-low colorectal cancer. The principal investigator at the Sloan-Kettering Institute for Cancer Research will conduct a biomarker-intensive Phase 2 clinical trial evaluating the safety and efficacy of combining T-DXD with the anti-EGFR...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $736,168 to the Sloan-Kettering Institute for Cancer Research to develop first-in-class antibody-drug conjugates (ADCs) and payloads specifically designed for combination with external beam radiotherapy. The key products and services to be delivered include: Developing HER2-directed ADCs containing DNA damage response inhibitors as payloads, which have demonstrated efficacy in vitro and...
- The National Cancer Institute (NCI) awarded a $215,311 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Texas Health Science Center at Houston (UTHealth) for the project "Preclinical Efficacy of GPR56 Antibody-Drug Conjugates and Combination Therapies for Triple-Negative Breast Cancer". The 24-month grant aims to develop and evaluate GPR56 antibody-drug conjugates (ADCs) as a novel targeted therapy for triple-negative breast cancer (TNBC),...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $695,004 to The University of Texas MD Anderson Cancer Center to conduct research aimed at "Deciphering the Structural Determinants of Response and Resistance to HER2-Targeted Antibody-Drug Conjugates and Tyrosine Kinase Inhibitors for HER2-Mutant Non-Small Cell Lung Cancer". The research seeks to better understand the structural factors that influence sensitivity...
- This Project Grant award, titled "INVESTIGATING MITOCHONDRIAL NETWORKS AS A CRITICAL DETERMINANT OF RESPONSE TO ANTIBODY DRUG CONJUGATES IN ADVANCED NSCLC", is funded by the National Cancer Institute under the Cancer Treatment Research federal grant program (CFDA 93.395). The $531,379 award, which runs from March 2025 to February 2030, aims to evaluate the role of mitochondrial networks in determining the response to antibody drug conjugates (ADCs) in advanced/metastatic non-small cell...
- The federal Project Grant award, valued at $1,690,396.00 and issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports epigenetic research on BRAF-mutant colorectal cancers at The University of Texas MD Anderson Cancer Center. The research aims to investigate the epigenetic mechanisms and targeting approaches during the response to BRAF inhibitor and anti-EGFR therapy for BRAF-mutant colorectal cancers. The award period runs from...
- This federal Project Grant award, funded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), provides $400,000.00 to Onconaut Therapeutics Inc. to develop novel combination therapies for the treatment of colorectal cancer. The project aims to evaluate the efficacy of combining FOLFIRI chemotherapy with CHD1L inhibitors (OTI-600 series), which have demonstrated antitumor activity as single agents and potential synergistic effects when combined with...
- This federal Project Grant award of $163,500.00 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research to develop new therapies for diffuse-type gastric cancer (DGAC). The primary awardee, The University of Texas MD Anderson Cancer Center, aims to unravel the mechanisms of DGAC tumorigenesis and apply that knowledge to lay a foundation for DGAC therapy development. Key objectives include determining the impact of drug candidates on DGAC stemness,...
- The University of Texas MD Anderson Cancer Center was awarded a $616,715 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) on August 11, 2025. The grant supports the development of a novel "Microbial-Inspired Immune-Stimulating Antibody-Toxin Conjugate (ATC) for Cancer Immunotherapy". The project aims to engineer an ATC that combines an anti-CD47 antibody with the Listeria monocytogenes toxin LLO, linked via a cleavable linker. This ATC is...